NCT02362789 - Secukinumab Study in PSOriasis Exploring pruRITUS Intensity and Lesional Biomarkers | Biotech Hunter

Enrollment

132

Participants

Timeline

Start Date

January 4, 2015

Primary Completion Date

July 15, 2016

Study Completion Date

July 15, 2016

Conditions

Psoriasis

Interventions

BIOLOGICAL

Secukinumab

150 mg secukinumab in 1 ml solution for subcutaneous injection (pre-filled syringe)

BIOLOGICAL

Placebo

Matching placebo in 1 ml solution for subcutaneous injection (pre-filled syringe)

Trial Locations (19)

10117

Novartis Investigative Site, Berlin

22391

Novartis Investigative Site, Hamburg

30625

Novartis Investigative Site, Hanover

33647

Novartis Investigative Site, Bielefeld

44803

Novartis Investigative Site, Bochum

45883

Novartis Investigative Site, Gelsenkirchen

48149

Novartis Investigative Site, Münster

48455

Novartis Investigative Site, Bad Bentheim

49074

Novartis Investigative Site, Osnabrück

56242

Novartis Investigative Site, Selters

60590

Novartis Investigative Site, Frankfurt

68167

Novartis Investigative Site, Mannheim

70176

Novartis Investigative Site, Stuttgart

70178

Novartis Investigative Site, Stuttgart

81675

Novartis Investigative Site, München

91054

Novartis Investigative Site, Erlangen

01744

Novartis Investigative Site, Dippoldiswalde-Schmiedeberg

07548

Novartis Investigative Site, Gera

04105

Novartis Investigative Site, Leipzig